No evidence or no alternative? Taking responsibility for off‐label prescribing

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Internal medicine journal (Print)

• Publication date

  2012-03-01

• Fields of study

  Law, Medicine

• Identifiers
  DOI 10.1111/j.1445-5994.2012.02713.xPMID 22432984
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Off-Label Use of Recombinant Factor VIIa in U.S. Hospitals: Analysis of Hospital Records

  2011cited by this paper
• Recombinant factor VIIa (NovoSeven RT) use in high risk cardiac surgery.

  2011cited by this paper
• The Case for Legal Regulation of Physicians' Off-Label Prescribing

  2011cited by this paper
• A Hemorrhage of Off-Label Use

  2011cited by this paper
• A retrospective case control study of recombinant factor VIIa in patients with intracranial haemorrhage caused by trauma

  2011cited by this paper
• Massive postpartum hemorrhage: recombinant factor VIIa use is safe but not effective.

  2011cited by this paper
• Recombinant activated factor VII safety in trauma patients: results from the CONTROL trial.

  2011cited by this paper
• Systematic Review: Benefits and Harms of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications

  2011cited by this paper
• A hemorrhage of off-label use.

  2011cited by this paper
• Safety of recombinant activated factor VII in randomized clinical trials.

  2011cited by this paper
• Information from Pharmaceutical Companies and the Quality, Quantity, and Cost of Physicians' Prescribing: A Systematic Review

  2010cited by this paper
• Safety of recombinant activated factor VII in randomized clinical trials.

  2010cited by this paper
• Off-label use of second-generation antipsychotic agents among elderly nursing home residents.

  2010cited by this paper
• Cost-effectiveness analysis and efficient use of the pharmaceutical budget: the key role of clinical pharmacologists.

  2010cited by this paper
• Off-Label Prescribing: A Call for Heightened Professional and Government Oversight

  2009cited by this paper
• Off-label prescribing to children in the United States outpatient setting.

  2009cited by this paper
• U.S. physician knowledge of the FDA‐approved indications and evidence base for commonly prescribed drugs: results of a national survey

  2009cited by this paper
• Going off-label without venturing off-course: evidence and ethical off-label prescribing.

  2009cited by this paper
• Variation in the use of recombinant activated factor VII in critical bleeding

  2009cited by this paper
• The promotion of olanzapine in primary care: an examination of internal industry documents.

  2009cited by this paper
• Off label and unlicensed prescribing in a specialist oncology center in Australia

  2009cited by this paper
• Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage.

  2008cited by this paper
• Use of Recombinant Activated Factor VII in Patients Without Hemophilia: A Meta-Analysis of Randomized Control Trials

  2008cited by this paper
• Off-label or off-limits?

  2008cited by this paper
• Physicians' liability for off-label prescriptions.

  2007cited by this paper
• Physicians' liability for off-label prescriptions.

  2007cited by this paper
• Off-label prescribing among office-based physicians.

  2006cited by this paper
• Off‐label use of medicines: consensus recommendations for evaluating appropriateness

  2006cited by this paper
• Positive outcomes through the appropriate use of off-label prescribing.

  2006cited by this paper
• Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: A systematic review

  2005cited by this paper
• Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial.

  2003cited by this paper
• Off-label or out of bounds? Prescriber and marketer liability for unapproved uses of FDA-approved drugs.

  2003cited by this paper
• Possible role of recombinant activated factor VII (rFVIIa) in the control of hemorrhage associated with massive trauma.

  2002cited by this paper
• An effective treatment of severe intractable bleeding after valve repair by one single dose of activated recombinant factor VII

  2001cited by this paper
• An effective treatment of severe intractable bleeding after valve repair by one single dose of activated recombinant factor VII.

  2001cited by this paper
• Successful treatment of severe intra‐abdominal bleeding associated with disseminated intravascular coagulation using recombinant activated factor VII

  2001cited by this paper
• Prescription of drugs during pregnancy in France.

  2000cited by this paper
• Treatment of traumatic bleeding with recombinant factor VIIa.

  1999cited by this paper

• Cost-Related Non-Adherence to Prescribed Medicines: What Are Physicians’ Moral Duties?

  2024cites this paper
• "Some sort of fantasy land": A qualitative investigation of appropriate prescribing in cancer care.

  2020cites this paper
• The enhanced danger of physicians’ off-label prescribing during a public health emergency

  2020cites this paper
• The significant cost of systematic reviews and meta-analyses: A call for greater involvement of machine learning to assess the promise of clinical trials

  2019cites this paper
• El uso off-label de los medicamentos: reflexión ético-legal y propuesta de mejora

  2017cites this paper
• The complex legal and ethical issues related to generic medications. Viral hepatitis: a case study

  2017cites this paper
• The role of fibrinogen and haemostatic assessment in postpartum haemorrhage: preparations for a randomised controlled trial.

  2015cites this paper
• Issues around the Prescription of Half Tablets in Northern Switzerland: The Irrational Case of Quetiapine

  2015cites this paper
• Prescribing practice and off-label use of psychotropic medications in post-acute brain injury rehabilitation centres: A cross-sectional survey

  2015cites this paper
• RBC Red Blood Cells FFP Fresh frozen plasma HES Hydroxyethyl starch RCT Randomised controlled trial FIB-PPH Trial acronym: “FIBrinogen as initial treatment for PostPartum Haemorrhage” GRADE Grading of Recommendations Assessment, Develop-

  2015influential citation
• The Spot Sign and Tranexamic Acid on Preventing ICH Growth – AUStralasia Trial (STOP-AUST): Protocol of a Phase II Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial

  2014cites this paper
• ‘Out of the frying pan’: the challenges of prescribing for insomnia in psychiatric patients

  2014cites this paper
• Ethical Justifications for Access to Unapproved Medical Interventions: An Argument for (Limited) Patient Obligations

  2014cites this paper
• Галстян Г.М., Колосова И.В. ПРИМЕНЕНИЕ РЕКОМБИНАНТНОГО АКТИВИРОВАННОГО ФАКТОРА VII СВЕРТЫВАНИЯ КРОВИ ДЛЯ ЛЕЧЕНИЯ ГЕМОРРАГИЧЕСКОГО СИНДРОМА У БОЛЬНЫХ С ТРОМБОЦИТОПЕНИЕЙ

  2014cites this paper
• Off‐label use of recombinant factor VIIa in two tertiary hospitals in Queensland

  2013cites this paper